Cargando…

Successful treatment of 2 patients with brain metastases from non-small cell lung cancer with epidermal growth factor receptor mutation receiving dacomitinib: A case report

RATIONALE: Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with brain metastasis, which is related to poor survival outcomes. The ability of tyrosine kinase inhibitor drugs to penetrate the blood–brain barrier makes them a potential option for intracranial metasta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Songchen, Cong, Xiaofeng, Liu, Ziling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322497/ https://www.ncbi.nlm.nih.gov/pubmed/34397694 http://dx.doi.org/10.1097/MD.0000000000026680

Ejemplares similares

Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report
por: Gao, Feng, et al.
Publicado: (2020)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Construction of a nomogram to predict the prognosis of non-small-cell lung cancer with brain metastases
por: Huang, Zhangheng, et al.
Publicado: (2020)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018)

Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report
por: Ma, Chunhua, et al.
Publicado: (2020)

Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study
por: He, Jinlin, et al.
Publicado: (2021)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
por: Zhou, Shunkai, et al.
Publicado: (2020)

Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data
por: Zhao, Songchen, et al.
Publicado: (2021)

Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review
por: Yang, Yi, et al.
Publicado: (2020)

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases: An Observational Study
por: Hu, Nan, et al.
Publicado: (2015)

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review
por: Falcone, Rosa, et al.
Publicado: (2018)

Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis
por: Duan, Hua, et al.
Publicado: (2020)

Association between polymorphisms of epidermal growth factor 61 and susceptibility of lung cancer: A meta-analysis
por: Chen, Quan, et al.
Publicado: (2020)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
por: Li, Yibin, et al.
Publicado: (2022)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report
por: Liu, Jing, et al.
Publicado: (2021)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

The impact of baseline brain metastases on clinical benefits and progression patterns after first-line crizotinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer
por: Chen, Yuqi, et al.
Publicado: (2021)

Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports
por: Gozzi, Elisa, et al.
Publicado: (2020)

First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Sertoli-Leydig cell tumor in two siblings with DICER1 syndrome: A case report and literature review
por: Zhang, Ying, et al.
Publicado: (2020)

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review
por: He, Guangzhao, et al.
Publicado: (2016)

Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis
por: He, Canfeng, et al.
Publicado: (2021)

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review
por: Dong, Yong, et al.
Publicado: (2021)

Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib
por: Aydiner, Adnan, et al.
Publicado: (2015)

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report
por: Yan, Hongxia, et al.
Publicado: (2020)

Brain metastases from esophageal cancer: A case report
por: Qie, Shuai, et al.
Publicado: (2020)

Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer
por: Lee, Dong Soo, et al.
Publicado: (2016)

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
por: Zhao, Wei, et al.
Publicado: (2022)

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
por: Hannan, Enda J., et al.
Publicado: (2017)

High Incidence of EGFR Mutations in Pneumonic-Type Non-Small Cell Lung Cancer
por: Liu, Jun, et al.
Publicado: (2015)

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature
por: Guo, Qiang, et al.
Publicado: (2023)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dn8jdfmocm84n42hdqhsv4kak5